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Abstract Structured exercise is considered an important
cornerstone to achieve good glycemic control and improve
cardiovascular risk proﬁle in Type 2 diabetes. Current
clinical guidelines acknowledge the therapeutic strength of
exercise intervention. This paper reviews the wide patho-
physiological problems associated with Type 2 diabetes
and discusses the beneﬁts of exercise therapy on phenotype
characteristics, glycemic control and cardiovascular risk
proﬁle in Type 2 diabetes patients. Based on the currently
available literature, it is concluded that Type 2 diabetes
patients should be stimulated to participate in speciﬁcally
designed exercise intervention programs. More attention
should be paid to cardiovascular and musculoskeletal de-
conditioning as well as motivational factors to improve
long-term treatment adherence and clinical efﬁcacy. More
clinical research is warranted to establish the efﬁcacy of
exercise intervention in a more differentiated approach for
Type 2 diabetes subpopulations within different stages of
the disease and various levels of co-morbidity.
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Type 2 diabetes: a modern, but not modest,
health threat
Already in the ﬁrst century, the ancient Greek physician
Aretaeus of Cappadocia described the term diabetes (di-
abaı´nein)a s‘ …a wonderful affection, not very frequent
among men…’[ 1]. However, it was not until 1675 that
Thomas Willis, an English physician, added the word
mellitus, as a reference to the sweet taste of a diabetes
patient’s urine. Whether this condition referred to Type 1
(autoimmune disease) or Type 2 (relative insulin deﬁ-
ciency) diabetes mellitus is unknown. However, it lasted
another 200 years before the French physician Lanceraux
made the distinction between diabetes in lean and obese
men: diabete gras and diabete maigre [2]. In the 1930 s, the
diabetologist Joslin c.s. noted that the incidence of diabetes
in lean individuals was relatively constant in each decade of
life, while diabetes in the obese was related to age [3].
Already in those days he attributed the increasing preva-
lence of diabetes in the 1930 s to increasing obesity [3].
The sharp rise in Type 2 diabetes prevalence during the
second half of the twentieth century ﬁrst occurred in
developing countries, parallel to the rapid socio-economic
development and dramatic changes in lifestyle in these
countries [4]. In traditionally more afﬂuent societies, the
prevalence of Type 2 diabetes showed a clear rise in
the early 1990 s [5, 6], almost parallel to the increase in the
prevalence of obesity [7]. Although genome-wide associ-
ation studies have revealed that certain single nucleotide
polymorphisms (SNPs) related to beta-cell function pre-
dispose to the development of Type 2 diabetes [8–11],
clinical characteristics such as obesity and lack of physical
activity are regarded as the most important risk factors,
both independently associated with diabetes and diabetes-
related co-morbidities [12–14].
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(IDF), the disease now affects 246 million people world-
wide and is expected to affect some 380 million by 2025,
representing as much as 7.1% of the global adult popula-
tion [15]. As such, the associated health burden in terms of
cardiovascular disease, kidney failure, blindness, amputa-
tions and premature death will increase progressively,
unless more effective primary and secondary pharmaceu-
tical and/or lifestyle interventional strategies become more
widely available.
Metabolic disturbances associated with Type 2 diabetes
Hyperglycemia in the insulin-resistant state
The main feature of Type 2 diabetes is formed by the
relative resistance to peripheral insulin action, resulting in
impaired glycemic control. According to WHO criteria,
someone is considered to have Type 2 diabetes if fasting
plasma glucose levels are equal or above 7.0 mmol/l or if
2 h following an 75 g oral glucose tolerance test (OGTT)
plasma glucose concentration rises C 11.1 mmol/l [16].
Although still subject of intense debate, these diagnostic
cut-off points have been based on epidemiological studies
that have examined the risk of developing retinopathy
over a range of plasma glucose levels [17]. However,
even in ‘high-risk’ obese subjects without blood glucose
abnormalities during an OGTT, real-life hyperglycemia
was already detectable for almost 14% throughout the day
[18]. This indicates that even in the absence of formal
intermediate hyperglycemia, as deﬁned by the IDF/World
Health Organisation (WHO) [17], so-called post-prandial
hyperglycemic spikes are probably an early feature of
the insulin-resistant state. The difﬁculties to manage this
post-prandial hyperglycemia were exempliﬁed in two of
our most recent continuous glucose monitoring studies in
Type 2 diabetes patients [19, 20]. In these studies, we
show that hyperglycemia is experienced for as much as
8–13 h/day under strict dietary standardization, but
otherwise free-living conditions. A strong correlation was
observed between the prevalence of hyperglycemia and
HbA1c content in the Type 2 diabetes patients, but even
patients with apparent acceptable glycemic control
(HbA1c B 7.0%) were still experiencing hyperglycemia
for 11 ± 0.9 h throughout the day [20]. It has been sug-
gested that these hyperglycemic blood glucose excursions
may contribute to the development of macro- and/or
microvascular complications in prediabetic states [21, 22].
However, many different pathophysiological pathways
may be simultaneously activated (see below). Therefore,
its separate contribution to macro- or microvascular
complications is currently unknown.
Hyperglycemia and beta-cell failure
The pathophysiological basis for aforementioned post-
prandial hyperglycemic spikes lies in a disturbed ﬁrst-
phase insulin response of the pancreatic beta-cell, which
normally suppresses endogenous glucose production.
Subsequently, beta-cell function further deteriorates and
endogenous insulin production is insufﬁcient to fully
compensate for the peripheral insulin insensitivity in
muscle, liver and/or fat cells [23]. Although the suscepti-
bility for a glucose-stimulated insulin secretory defect has a
genetic origin [24], it only becomes apparent in the context
of peripheral insulin resistance [25, 26]. Once the beta-cell
fails, post-prandial hyperglycemia may induce large
amounts of reactive oxygen species (ROS) that can cause
further damage to cellular components of insulin produc-
tion and induce apoptosis in beta-cells [27]. In addition,
lipotoxicity [28] and possibly also amyloid deposits [29]
may contribute to further deterioration of beta-cell func-
tion. Certain drugs, such as sulfonylurea (SU) derivatives,
are still widely applied to stimulate glucose-dependent
insulin release. Although these drugs temporarily improve
glucose homeostasis, they do not restore beta-cell function
and may accelerate loss of long-term glycemic control
[30]. In a quest to improve long-term diabetes outcome, a
whole new line of drugs has become available that try to
mimic the release of speciﬁc gut hormones [31]. These
incretin mimicking drugs have been shown to improve
islet-cell function, and both fasting and post-prandial gly-
cemic control [32–36]. Nevertheless, more long-term efﬁ-
cacy of incretin mimicking drugs should be awaited before
their clinical value as a mono- or add-on therapy can be
established [37–39]. Besides medication, dietary measures
such as slowly digestible carbohydrates [40] and the
application of amino acid induced insulin secretion [41–43]
and/or high protein diets [44] can modulate post-prandial
hyperglycemia as well. As such, structured lifestyle inter-
ventions combined with metformin remain the ﬁrst treat-
ment of choice. If oral dose adjustment is not sufﬁcient to
meet therapeutic targets, early exogenous insulin therapy
should be initiated [45].
Obesity and insulin resistance
Over the past three decades, the etiology of insulin resis-
tance and beta-cell dysfunction has been subject to intense
study [23, 46]. Obesity, as a result of inactivity in combi-
nation with overeating, plays a key role in the development
of pancreatic beta-cell dysfunction as well as insulin
resistance. Several mechanisms mediating this interaction
have been identiﬁed. It is now well established that a
number of circulating hormones, cytokines, and metabolic
fuels, such as non-esteriﬁed fatty acids (NEFAs), are being
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123released by adipose tissue and can modulate insulin action.
An increased mass of stored triglyceride, especially in
visceral or deep subcutaneous adipose depots, leads to
large adipocytes that are themselves resistant to the ability
of insulin to suppress lipolysis. This results in increased
release and circulating NEFA and glycerol levels. Both
aggravate insulin resistance in skeletal muscle [47, 48] and
the liver [49, 50].
Adipokines and chronic inﬂammation
Besides increased concentrations of NEFA, expanded vis-
ceral adipose tissue also releases pro-inﬂammatory cyto-
kines [e.g., tumor necrosis factor a (TNF-a), interleukin-6
(IL-6), monocyte chemoattractant protein-1 (MCP-1)].
Pathways regulating suppression of cytokine signaling
proteins [51] and inducible nitric oxide synthase [52] may
be involved in mediating cytokine-induced insulin resis-
tance. Secretion of these cytokines, particularly MCP-1 by
adipocytes, endothelial cells and monocytes, increases
macrophage recruitment and subsequently ampliﬁes cyto-
kine-induced insulin resistance in a feed forward manner
[53]. TNF-a and IL-6 act through classical receptor-med-
iated processes, resulting in upregulation of potential
mediators of systemic inﬂammation that can lead to insulin
resistance.
More recently, a new adipokine, named retinol binding
protein-4, has been discovered that is directly linked to the
level of obesity-induced insulin resistance, both in cross-
sectional [54, 55] and longitudinal studies [54, 56–58].
Another adipokine, subject to intense study, is adiponectin.
Low adiponectin levels have been correlated with visceral
obesity and whole-body insulin sensitivity [59]. This fat
cell hormone acts as an insulin sensitizer, inhibiting tri-
glyceride formation in liver and stimulating fatty acid
oxidation in muscle in an AMP-activated protein kinase
(AMPK) and peroxisome proliferators activated receptor
alpha (PPAR-a)-dependent way [60]. Despite their appar-
ent importance in the insulin resistance syndrome, afore-
mentioned adipokines are just examples of a family of
adipocyte-derived factors that modulate insulin resistance
and systemic inﬂammation. Besides new adipokines, also
certain myokines now appear to affect insulin sensitivity
and inﬂammatory responses [61]. As such, the list of
insulin (de)sensitizing proteins and cytokines is still far
from complete.
Ectopic fat storage causes insulin resistance
in muscle and liver
In the context of a low habitual physical activity level and
low oxidative capacity, excess intramyocellular lipid
(IMCL) storage has been associated with skeletal muscle
insulin resistance [62]. In accordance, intervention studies
indicate that insulin sensitivity can change independently
of IMCL contents [63–68]. Indeed, not IMCL content
itself, but rather the peroxidation of inactive pools of IMCL
and intra-cellular fatty acids may explain the apparent
correlation between IMCL content and insulin resistance
[69]. In addition, intra-cellular lipid metabolites such as
diacylglycerol (DAG), long chain fatty-acyl CoA and
ceramides have been shown to interfere with the insulin
signaling pathway [70]. These metabolites activate a pro-
tein kinase leading to the phosphorylation of serine/threo-
nine sites on the insulin receptor substrate 1, subsequently
hampering glucose transport activity and insulin-stimulated
myocellular glucose uptake [71].
Ectopic fat storage in hepatocytes, so-called intrahepatic
lipids (IHL), has also been related to the development of
hepatic insulin resistance [72] and hepatic inﬂammation,
initiating non-alcoholic fatty liver disease [73]. In rodents,
3 days of a high-fat diet induces hepatic insulin resistance,
while no signiﬁcant changes in fat content in muscle or
visceral tissue could be detected [74]. Experimental
research now suggests that hepatic insulin resistance arises
from DAG-induced activation of protein kinase Ce, which
directly binds to and inhibits insulin receptor tyrosine
kinase activity [75]. As such, fat-induced hepatic insulin
resistance and hepatic inﬂammation are considered
important etiological factors in the development of sys-
temic insulin resistance.
Glucolipotoxicity and long-term complications
in Type 2 diabetes
Besides inhibiting intra-cellular insulin signaling, afore-
mentioned metabolic disturbances in glucose and fat
metabolism increase the formation of Amadori-glycated
proteins and advanced glycation end-products (AGE)
impairs receptor function for AGE (RAGE) and increases
exposure to ROS in almost any organ system [76–78].
Chronic exposure to Amadori products, AGE and ROS,
so-called glucolipotoxicity, can cause vasculopathy [76],
glomerulopathy [79, 80] and potentially also induce nerve
cell damage [81]. In accordance, hyperglycemia-induced
AGE and ROS formation provide a unifying model for the
high incidence of microvascular disease, retinopathy,
nephropathy [80, 82], and possibly also neuropathy [83]
prevalent in long-term Type 2 diabetes [84]. In accordance,
certain pharmaceutical [85, 86], nutritional [81] and/or
exercise interventions [87–89] that modulate AGE, RAGE
and/or ROS formation have been reported to improve
insulin sensitivity in experimental rodent models. In
humans, both structured exercise and alpha lipoic acid have
been suggested to reduce neuropathic symptoms [90, 91].
However, it is unknown whether such a combined and
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prevent diabetes-related complications [92].
Reduced oxidative capacity and mitochondrial function
in insulin-resistant states
It has been well established that most patients with Type 2
diabetes have a signiﬁcantly lower oxidative capacity
(VO2peak) than age-matched controls [93–95]. Whether this
lower oxygen uptake capacity is attributed to a low habitual
physical activity level, reduced mitochondrial content or an
intrinsic mitochondrial defect is a topic of intense debate
[96–109]. Recent experimental evidence indicates that
mitochondrial respiration is not abnormal when normalized
for mitochondrial content [104, 110], which implies that
low habitual physical activity level and/or cardiovascular
dysfunction may explain the generally deconditioned state
in the Type 2 diabetes patient [97, 106]. Although the
debate will probably continue whether the lower oxidative
capacity represents either cause or consequence [97, 111],
future exercise studies should be aimed at answering the
question whether a substantial long-term increase in
physical activity level by implementing a well-structured
exercise intervention program can reverse the decondi-
tioned state of Type 2 diabetes patients and improve the
metabolic proﬁle.
Hyperinsulinemia, autonomic dysregulation
and cardiovascular disease
Above-mentioned metabolic disturbances in oxidative
capacity, glucose homeostasis and fat metabolism not only
affect systemic insulin resistance, but also appear to
inﬂuence long-term energy homeostasis [112]. Animal
studies indicate that long-term energy balance is coordi-
nated through the combined action of insulin and leptin in
the brain [113]. Interestingly, these studies have suggested
that insulin action in certain hypothalamic centers reduces
food intake while increasing sympathetic nervous system
(SNS) outﬂow to brown adipose tissue to produce heat
from fatty acid oxidation as a mechanism to increase
energy expenditure [113]. As such, these chronically ele-
vated insulin [114, 115] and leptin concentrations [116]
further contribute to obesity-associated hypertension
through activation of the SNS and release of catechola-
mines in the basal state [117]. Indeed, early-stage insulin
resistance appears to cause sympathovagal imbalance in
normoglycemic, insulin-resistant offspring of Type 2 dia-
betes patients [118]. Also in more advanced insulin-resis-
tant states, aforementioned increases in sympathetic tone
have been associated with changes in cardiac and vascular
function that lead to hypertension, left ventricular dys-
function and/or cardiac autonomic neuropathy [119]. Such
changes set the stage for arrhythmia, silent infarction and
sudden death [120, 121]. Because potentiation of athero-
genesis and cardiac dysfunction occurs in the presence of
early diabetic symptoms as well as in the established dis-
ease [122, 123], early implementation of strategies to
reduce cardiovascular risk factors and to attenuate diabetes
progression may help to improve long-term outcomes for
at-risk individuals. Such interventions may include well-
established pharmaceutical treatments for hypertension and
dyslipidemia, dietary modulation and/or energy restriction,
weight loss, and exercise intervention [121].
Exercise as opposed to pharmaceutical therapy
in Type 2 Diabetes
Over the past 5 years, both lipid lowering therapy [124,
125] and blood pressure lowering therapies [126, 127] have
been proven effective to improve cardiovascular outcome in
Type 2 diabetes patients. The effectiveness of these drugs
may explain why the additive beneﬁts of intensive glycemic
control are more difﬁcult to demonstrate, even in large and
long-term clinical trials such as ACCORD, ADVANCE and
VADT [128]. Nevertheless, much effort is currently put into
the discovery of novel pharmacological solutions that may
further improve metabolic control and prevent diabetes-
related co-morbidities. Although the combination of intense
blood pressure and blood glucose lowering therapy has been
shown to reduce (microvascular) complications [129–131],
stringent application of multiple blood glucose lowering
drugs does not necessarily result in a further reduction of
macrovascular events [130, 132–135]. Especially, in more
advanced Type 2 diabetes, more intensive blood glucose
lowering strategies may have counter-balancing conse-
quences for cardiovascular disease, such as hypoglycemia,
weight gain, or other metabolic changes [128]. Although
results of long-term intervention studies are underway, the
current increase in Type 2 diabetes incidence and con-
comitant cardiovascular co-morbidities may beneﬁt more
from therapeutic strategies entailing structured exercise
interventions with [136–138] or without [137, 139, 140]
dietary modulation and/or oral blood glucose lowering
medication [136, 141, 142].
Does exercise reverse chronic inﬂammation?
In insulin-resistant populations, several adipokines, such as
leptin and adiponectin, as well as muscle contraction-
induced factors, so-called myokines (i.e., IL-6), have been
shown to modulate insulin resistance and inﬂammatory
status [143]. Although there is consensus that weight loss is
associated with an increase in adiponectin and decreased
levels of leptin, TNF-a and high sensitivity C-reactive
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effects of exercise without concomitant weight loss
are limited and produce somewhat inconsistent results
[146–148]. Nevertheless, the ﬁnding in longitudinal studies
that regular exercise training induces a reduction in hsCRP
indicates that physical activity may help to suppress sys-
temic low-grade inﬂammation [149–151]. An experimental
study using endotoxin-induced chronic inﬂammation
showed that physical exercise directly inhibits endotoxin-
induced TNF-a production in humans, most likely through
IL-6 release from exercising muscle [152]. Clearly, more
long-term intervention studies are warranted to see to what
extent the proposed anti-inﬂammatory effect of exercise
training modulates peripheral insulin sensitivity in Type 2
diabetes patients.
Exercise as an antihypertensive agent
Besides improving glycemic control, a recent meta-analysis
showed that structured exercise intervention studies in non-
insulin-dependent Type 2 diabetes patients reduce systolic
blood pressure with -4.16 mmHg (95% CI -9.46 to 1.14)
[153]. Such reductions in mean arterial blood pressure are
clinically relevant and are similar to the effects of add-on
blood pressure lowering therapy using a combination of an
ACE inhibitor and thiazide diuretic [126]. Although both
resistance- and endurance-type exercise seem to reduce
mean arterial blood pressure to a similar extent in Type 2
diabetes populations [154], further research is needed to
explore their separate contribution and way of action in
different insulin-resistant (sub)populations.
Does exercise therapy improve lipid metabolism?
Although fasting blood lipid proﬁles in Type 2 diabetes
populations have been shown to improve following long-
term exercise interventions with [136, 137, 155] or without
dietary restriction [142, 156], recent exercise intervention
studies in Type 2 diabetes patients showed few to no
additional beneﬁts on top of lipid lowering agents [146,
157]. The latter may be related to the lack of a simulta-
neously diet-induced weight loss [158], a compensatory
decline in daily physical activity level [159] or the fact that
in most Type 2 diabetes populations baseline total-cho-
lesterol, LDL-cholesterol and triglycerides levels were
already 15–35% lower in comparison with aforementioned
‘exercise-only’ intervention studies [142, 156]. Neverthe-
less, in accordance with earlier reports (for references see
[160]), detailed body composition analyses using dual
energy X-ray absorptiometry (DEXA) and MRI revealed
that, despite an unaltered body weight, 5–6 months of
combined endurance and resistance type of exercise train-
ing is able to induce regional changes in fat and lean muscle
mass in obese Type 2 diabetes patients [146, 157]. Indeed,
several lines of research [68, 161–163] now indicate that
exercise interventions of sufﬁcient volume and intensity
may also modulate post-prandial lipid handling. Interest-
ingly, higher levels of habitual physical activity were
reported to be strongly associated with reduced IHL content
[164], while intervention studies using dietary or exercise
intervention report somewhat contrasting results [165, 166],
supporting the idea that nutritional modulation may be more
effective in reducing IHL content. Future studies should
aim to unravel the mechanisms of action and modulating
effects of different modes of exercise training on post-
absorptive and post-prandial lipid handling in Type 2 dia-
betes patients [167]. Ideally, dietary intake and hormonal
responses should be monitored to differentiate between the
impact of isocaloric exercise bouts of different volumes and
intensities on both post-prandial glycemia and lipidemia.
Exercise prescription in Type 2 diabetes
Current guidelines from the American Diabetes Associa-
tion (ADA), the European Association for the Study of
Diabetes (EASD) or the American College of Physicians
(ACP) all acknowledge the therapeutic strength of exercise
intervention [45, 168–170]. The ADA states that ‘to
improve glycemic control, assist with weight maintenance,
and reduce risk of CVD, at least 150 min/week of moder-
ate-intensity aerobic physical activity is recommended and/
or at least 90 min/week of vigorous aerobic exercise, …
distributed over at least 3 days/week and with no more
than 2 consecutive days without physical activity.’ Since
2006, the ADA guidelines explicitly mention and recognize
that ‘in the absence of contraindications, people with Type
2 diabetes should be encouraged to perform resistance
exercise 3 times a week, targeting all major muscle groups,
progressing to 3 sets of 8–10 repetitions at a weight that
can not be lifted more than 8–10 times’[ 169]. However,
these clinical guidelines generally do not include detailed
information on the preferred type and intensity of exercise
that should be applied to maximize the beneﬁts of exercise
for different subgroups of Type 2 diabetes patients and
further research is needed.
Acute versus more longer term exercise responses
Both a single bout of endurance- [171] and resistance-type
exercise [172, 173] have been shown to improve whole-
body insulin sensitivity and/or oral glucose tolerance.
Therefore, both types of exercise are of therapeutic use in
an insulin-resistant state [154]. The acute effects of exer-
cise on skeletal muscle insulin sensitivity are attributed to
the prolonged activation of the skeletal muscle glucose
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cle glycogen stores [174, 176–178], and/or increased
skeletal muscle blood ﬂow following the cessation of
exercise [179]. The glucoregulatory beneﬁts of either type
of exercise training are represented by the sum of the
effects of each successive bout of exercise [178]. In addi-
tion, more prolonged exercise training is accompanied by a
more structural adaptive response. For instance, endurance
training may upregulate mitochondrial enzyme activity in
skeletal muscle and subsequently improve whole-body
oxygen uptake capacity [180, 181]. However, the latter
response may be attenuated in more advanced and older
Type 2 diabetes patients [146, 182–185]. On the other
hand, resistance-type exercise is able to induce muscle
protein synthesis [186, 187] and, as such, represents an
effective interventional strategy to increase lean body mass
in both early [188] and advanced stage Type 2 diabetes
patients [146, 189].
Exercise modality
In terms of physiological adaptations, apparent differences
exist in the long-term adaptive response to endurance- or
resistance-type exercise training. Prolonged endurance-
type exercise training has been shown to improve insulin
sensitivity in both young [190], elderly [191] and/or insu-
lin-resistant subjects [178, 192–194]. The latter is attrib-
uted to the upregulation of skeletal muscle GLUT-4
expression, improved nitric oxide-mediated skeletal muscle
blood ﬂow and concomitant induction of weight loss [195],
reduced hormonal stimulation of hepatic glucose output
[196] and the normalization of blood lipids [197]. Long-
term resistance-type exercise interventions have also been
reported to improve glucose tolerance [157] and/or whole-
body insulin sensitivity [172, 188, 198]. Besides the
consecutive effects of each successive bout of exercise in
acutely reducing glycogen stores [173, 199], resistance-
type exercise training has been associated with a sub-
stantial gain in skeletal muscle mass, thereby improving
whole-body glucose disposal capacity [172]. Besides the
attenuation of the loss of muscle mass with aging, resis-
tance-type exercise training also improves muscle strength
and functional capacity, thereby allowing a healthier, more
active lifestyle. Some studies report even greater beneﬁts of
resistance as opposed to endurance-type exercise training
on glycemic control and insulin sensitivity in long-standing
Type 2 diabetes patients [182]. However, recent evidence
indicates that both types of exercise interventions have
similar therapeutic strength in uncomplicated Type 2 dia-
betes patients [157]. Its combined application is probably
more effective, especially in patients with HbA1c lev-
els C 7.5% [157]. As such, it has been ﬁrmly established
that both endurance- and resistance-type exercise training
can be applied to improve metabolic control and quality of
life in Type 2 diabetes patients [154].
Energy expenditure determines therapeutic strength
of exercise
When prescribing exercise as treatment for an individual
diabetes patient, it is important to estimate total energy
expenditure that can be achieved through the recommended
type of exercise. Several studies have shown that the
energy equivalent of an endurance exercise bout represents
the major determinant of the exercise-induced changes in
glucose homeostasis [200–202]. To obtain durable meta-
bolic improvements through exercise, the absolute mini-
mum dose of weekly energy expenditure should entail
4.2 MJ (&1,000 kcal) [202], but for optimal results weekly
energy expenditure should probably be twice as high [202,
203]. Therefore, a lesser exercise intensity should be
compensated for by an increase in exercise duration.
Exercise in advanced stage Type 2 diabetes patients
Another expanding Type 2 diabetes subpopulation is
formed by the long-standing, insulin treated, Type 2 dia-
betes patients [204]. These patients generally suffer from
severe exercise intolerance due to the combination of low
oxidative capacity [205], micro- and macrovascular disease
[206, 207], neuropathy-related muscle weakness [207–210]
and/or sarcopenia [211]. As generic exercise intervention
programs are too demanding for most of these patients, it is
of utmost importance to implement intermediate exercise
intervention programs. Such intermediate programs are
needed to bring the patient to a level at which they are able
to participate in more generic diabetes intervention pro-
grams. Such intermediate programs should implement
short, relatively high-intensity, exercise bouts applied in an
intermittent fashion with the intention to increase muscle
strength and functional performance. These so-called short
‘ins-and-outs’ exercises do not produce feelings of dysp-
noea or discomfort and have been proven safe and effective
in cardiac patients [212, 213]. The efﬁcacy and safety of
such intermediate programs in long-standing Type 2 dia-
betes patients with high cardiovascular risk proﬁle was
recently conﬁrmed in a small scale study by our research
group [146]. Nevertheless, more larger scale trials are
warranted since exercise intervention studies generally
exclude this speciﬁc Type 2 diabetes subpopulation.
Interaction between exercise and blood glucose
lowering medication
Type 2 diabetes is characterized by resistance to the
actions of insulin in the presence of defects in insulin
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the disease; early stages tend to be characterized by a
compensatory hyperinsulinemic state, but progressive
beta-cell failure eventually occurs in most patients, lead-
ing to low basal fasting insulin levels [214]. Circulating
insulin plays a critical role in regulating hepatic glucose
output during exercise and has been shown to modulate
peripheral glucose uptake during exercise and recovery
[215–217]. Depending on the remaining insulin secretory
capacity, the use of insulin secretagogues [183, 218, 219],
the type of exogenous insulin used [220], as well as the
level of peripheral insulin resistance, the glucose lowering
effect of single bout of resistance or endurance bout of
exercise may vary considerably. Moreover, as discussed
in aforementioned paragraphs, the type, intensity and
duration of exercise may result in different glycemic
responses [182]. In accordance, failure to adequately
adjust medication and/or carbohydrate supplementation
can result in inappropriate swings in blood glucose levels,
either too low or too high. In accordance with Type 1
diabetes patients [221, 222], antecedent hypoglycemia
may also result in hypoglycemia unawareness in Type 2
diabetes [223] However, circumstances that result in
inappropriate elevations in blood glucose levels (such as
excessive carbohydrate supplementation or too large
reductions in insulin dosage) also have long-term adverse
implications [224–226]. Knowledge of the factors that
affect glucose metabolism is critical for designing strat-
egies to minimize inappropriate swings in blood glucose
control related to exercise. As such, more research is
required to better understand the complex interaction
between the different exercise modalities and blood glu-
cose lowering drugs. Nevertheless, in long-standing
insulin-treated Type 2 diabetes patients, we have shown
that frequent self-monitoring of blood glucose levels
before and after each exercise bout is safe and feasible
and results in improved glycemic control [146, 227].
Prevention of overload injuries in exercise training
Many patients with Type 2 diabetes experience not only
cardio-respiratory [205], but also musculoskeletal de-
conditioning [207–210]. Obesity- and diabetes-related
subclinical osteoarthritis [228, 229] on top of neuropathy-
related peripheral muscle weakness [210] have shown
potential reasons for overload injuries and subsequent drop
out [157, 230]. In future, endurance type of exercise
interventions, certain overuse injuries, might be prevented
through adaptations in biomechanical loading on feet and
lower extremities [231–234] as well as through the appli-
cation of resistance-type exercise aimed at strengthening
myotendinous structures. The latter concept is supported by
resistance-type exercise studies that report long-term
program adherence between 68% [235] and 72% [236],
without concomitant musculoskeletal overuse injuries.
Nevertheless, more long-term tailored exercise intervention
studies are needed to assess the usefulness of a differenti-
ated approach.
Long-term program adherence in therapeutic exercise
intervention programs
Long-term program adherence may vary between as much
as 10 and 80% [142, 230, 235, 237, 238]. Therefore,
motivational factors and time constraints should be con-
sidered to prevent long-term drop out rate. In accordance,
future exercise interventions might beneﬁt from psycho-
logical strategies such as motivational interviewing [239]
or booster sessions [240–242]. Furthermore, restricting the
travel time toward a training facility [243] and providing
the patient with feedback on physical activity levels [244]
may improve long-term adherence as well. Although
aforementioned approaches are likely to reduce program
drop out throughout the course of a supervised exercise
program, scientiﬁc studies are warranted that combine
aforementioned approaches.
Safety considerations before initiating exercise therapy
Before exposing patients with Type 2 diabetes to more
vigorous exercise programs, the ADA and U.S. Preventive
Services Task Force recommend exercise testing for silent
myocardial ischemia (SMI) if 10-year cardiovascular risk
exceeds 10% [169, 245]. Cardiac dysfunction [246] and
SMI are estimated to be present between 6 and 22% [247]
of the Type 2 diabetes patients, with cardiac autonomic
dysfunction, disease duration and male gender being the
best predictors for SMI [247]. Moreover, poor physical
ﬁtness [248], scintigraphy abnormalities [249], diabetic
retinopathy [249] and an advancing age[60 years [250]i n
combination with the traditional cardiac risk factors also
represent good predictors for the likelihood of a cardiac
event. The UKPDS Risk Engine v2.0 (available free of
charge at www.dtu.ox.ac.uk) may be of help to calculate an
individual patient’s risk for coronary heart disease [251].
Although arbitrary, the UKPDS Risk Engine indicates that
ECG stress testing in Type 2 diabetes is useful in most
patients with[2 cardiovascular risk factors, in middle-
aged patients with a diabetes duration[5 years, as well in
elderly patients[70 years. Although a stress ECG is not
the most sensitive diagnostic tool to detect SMI [252] and
predict coronary events [253], other research indicates that
it is still the most cost-effective tool when trying to mini-
mize the risk of a coronary event [254]. In case SMI
is expected, more sensitive diagnostic tests such as myo-
cardial perfusion scintigraphy [255], electron beam
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123computerized tomography [256] and/or coronary angiog-
raphy [257] should be considered before more vigorous
exercise is prescribed. Even in the absence of SMI, a stress
test will detect chronotropic incompetence [258] as well as
exercise-related hypertension and provide more objective
information on the individual ﬁtness level [205]. Ideally,
this information should be used to further tailor an exercise
program for the individual patient with Type 2 diabetes
[259].
Are structured exercise interventions cost-effective?
Previous lifestyle intervention studies indicate that long-
term health beneﬁts mainly depend on long-term program
adherence as well as the level of motivation, coaching and
supervision [235, 236, 260–263]. Depending on the level
and duration of exercise supervision and dietary guidance,
direct health care costs vary between *400 and *2,000
euro per individual participant [230, 264]. Although the
cost-effectiveness of such (theoretical) interventions is
more favorable in groups with high-risk populations com-
pared with mixed populations [264], lifestyle intervention
is considered highly cost-effective for the prevention of
Type 2 diabetes [264–270]. As far as we know, no study
has been published on the cost-effectiveness of similar
lifestyle interventions in patients that have already devel-
oped Type 2 diabetes. However, direct costs of either a
brisk walking or medical ﬁtness program in Type 2 dia-
betes seem to be within the aforementioned range [230].
Although we could not determine the cost-effectiveness in
the latter study, several larger scale multidisciplinary life-
style interventions (e.g., the ‘BeweegKuur’ in the Nether-
lands [265] and the LookAHEAD study in the USA) [271]
are underway. These studies should provide more insight
into the cost-effectiveness of well-structured exercise
interventions as a part of a multidisciplinary Type 2
diabetes care program consisting of medication, diet and
exercise.
Future research
Based on a thorough review of the literature, we recently
have proposed a more differentiated approach for exercise
therapy in Type 2 diabetes [259]. However, before more
differentiated exercise prescription guidelines can be used
as clinical treatment guidelines, its medium to long-term
efﬁcacy should ﬁrst be evaluated in more large-scale
randomized controlled clinical trials. By deﬁnition, most
randomized clinical trials completely disregard a patient’s
free choice or preference for a speciﬁc type of exer-
cise. In fact, potentially interested patients may feel
excluded, while others may ﬁnd it difﬁcult to adhere to a
non-preferred type of exercise intervention. Therefore, to
simulate a more realistic type of health care environment,
randomized clinical trials should be performed in which
subjects can choose from different exercise programs.
Moreover, for each type of exercise intervention, control
groups should perceive a similar amount of supervision and
guidance. Such an approach is likely to result in higher
adherence rates and will provide us with more deﬁnitive
answers on how to implement exercise therapy more
effectively in the chain of diabetes health care.
On top of these clinical and methodological issues,
recent studies suggest that genetic factors [272, 273] should
be considered to determine which subgroup Type 2 dia-
betes patients is likely to beneﬁt the most from tailored
exercise interventions. However, to unravel the proposed
genetic inﬂuences, well-deﬁned exercise intervention
studies with a high compliance rate will be essential.
Although such mechanistic studies often do not represent a
realistic clinical approach, these studies should provide
more insight into the pathomechanics of exercise inter-
vention in Type 2 diabetes patients with a different genetic
and/or co-morbidity proﬁle. The combined approach of
mechanistic and clinical implementation studies is expec-
ted to lead toward more speciﬁc and evidence-based
exercise prescription guidelines that can optimize long-
term therapeutic outcome at an affordable socio-economic
cost price. Given the size and expanding nature of the Type
2 diabetes pandemic, the ﬁeld of clinical diabetes research
has the scientiﬁc, socio-economic and medical ethical
obligation to contribute to such studies and move the ﬁeld
of diabetes care into action.
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Creative Commons Attribution Noncommercial License which per-
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